SentryX closes €3.2M seed funding round for the development of next generation pain relief therapeutics
We are delighted with the new investment in SentryX, a next generation, innovative pain relief therapy platform, focusing on orthopedic surgical post-procedural pain.
TargED Biopharmaceuticals appoints Ludo Haazen, M.D. as Chief Medical Officer
TargED Biopharmaceuticals, a biotech spin-off of the University Medical Center Utrecht, today announced the appointment of Ludo Haazen as Chief Medical Officer (CMO).
NTrans Technologies closes Series A investment to accelerate development of gene editing therapy
We’re excited to be investing in NTrans Technologies BV, a gene editing therapy company focusing on Duchenne Muscular Dystrophy, together with Essential Ventures, BOP Capital and Starfish Innovations.
Moveshelf closes seed investment to accelerate digital transformation of diagnosis and care for movement disorders
We proudly announce UHSF’s second investment, in Moveshelf, together with Locapes Investment Fund. Moveshelf is a digital health company with a unique platform for clinical movement analysis.
Interview with the TargED team and learn more about this exciting venture and its team!
In November 2020, TargED Biopharmaceuticals from Utrecht, The Netherlands, announced that they closed a seed investment round, and agreed on a public-private partnership with the UMC Utrecht. For the Utrecht Health Seed Fund, this marked their first closing since opening the fund for investments in April 2020.
